Transvaginal Cholecystectomy Versus Laparoscopic Cholecystectomy in Patients With Biliary Colic

Sponsor
Yale University (Other)
Overall Status
Completed
CT.gov ID
NCT00963950
Collaborator
(none)
30
2
55

Study Details

Study Description

Brief Summary

A safe and effective transvaginal approach accessing the abdominal cavity through the vagina rather than the abdominal wall is today considered a routine approach for many gynecologic surgeries.

First described by Dr. Ott in Germany in 1901, it is used routinely for transvaginal surgery, for example, transvaginal hysterectomies. This transvaginal technique has been shown to compare favorably to a laparoscopic abdominal approach because of less postoperative pain, the total elimination of abdominal wall hernias and wound infections, earlier recovery and better cosmesis.

Although routinely used in gynecological surgery, the advantages of the vaginal approach have not been utilized for general surgery applications such as cholecystectomies. Open or laparoscopic cholecystectomy accessing the abdominal cavity through abdominal wall incisions is currently still considered the standard of care in general surgery for patients with symptomatic gallbladder disease.

The investigators intend to access the abdominal cavity through the posterior vaginal fornix instead of the transabdominal approach that is now performed routinely. So far, this method of accessing the abdominal cavity through the transvaginal approach for the purpose of performing intraabdominal general surgery.

The investigators' transvaginal approach has the strong potential to further decrease invasiveness and take minimally invasive surgery to the next level in order to benefit the patient even more by minimizing postoperative pain, eliminating the risk of abdominal hernias and wound infections, improving cosmetic appearance and enabling the patient to return to routine activity and work earlier. First preliminary studies show these advantages but further research needs to be done to confirm these early positive results.

Condition or Disease Intervention/Treatment Phase
  • Procedure: transvaginal cholecystectomy
  • Procedure: laparoscopic cholecystectomy
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Transvaginal Cholecystectomy
Study Start Date :
Aug 1, 2009
Actual Primary Completion Date :
Sep 1, 2013
Actual Study Completion Date :
Mar 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention group

transvaginal cholecystectomy

Procedure: transvaginal cholecystectomy
Transvaginal approach to gallbladder removal.

Active Comparator: laparoscopic cholecystectomy

Laparoscopic cholecystectomy (4 port)

Procedure: laparoscopic cholecystectomy
laparoscopic cholecystectomy

Outcome Measures

Primary Outcome Measures

  1. feasibility of transvaginal cholecystectomy [2 year]

Secondary Outcome Measures

  1. pain [2 years]

  2. quality of life [2 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Female.

  • Age between 18 and 65 years old.

  • Biliary dyskinesia with documented Gallbladder EF < 30% or diagnosis of biliary colic with documented gallstones or polyps by imaging.

  • Body Mass Index (BMI) < 45 kg/m2.

Exclusion Criteria:
  • Any female patient, who is pregnant, suspected pregnant, or lactating.

  • Any patient with acute or acalculous cholecystitis.

  • Any patient with an American Society of Anesthesiologists Score > 3.

  • Any patient who is undergoing Peritoneal Dialysis (PD).

  • Patients who are taking immunosuppressive medications or are immunocompromised.

  • Patients on blood thinners or aspirin or abnormal blood coagulation tests.

  • Patients who have a history of prior open abdominal surgery or prior transvaginal surgery.

  • Patients with a history of ectopic pregnancy, pelvic inflammatory disease (PID) or severe endometriosis.

  • Non English speaking patients.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Yale University

Investigators

  • Principal Investigator: Kurt Roberts, MD, Yale University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT00963950
Other Study ID Numbers:
  • 0902004771
First Posted:
Aug 24, 2009
Last Update Posted:
Jan 17, 2018
Last Verified:
Jan 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yale University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 17, 2018